Ignite Creation Date:
2024-10-26 @ 3:40 PM
Last Modification Date:
2024-10-26 @ 3:40 PM
Study NCT ID:
NCT06590857
Status:
RECRUITING
Last Update Posted:
None
First Post:
2024-09-03
Brief Title:
Trial of 225Ac-DOTATATE RYZ101 Alone and with Pembrolizumab in Subjects with ER HER2-negative Unresectable or Metastatic Breast Cancer Expressing SSTRs
Sponsor:
None
Organization:
None
Study Overview
Official Title:
Phase 1b2 Open-label Trial of 225Ac-DOTATATE RYZ101 Alone and in Combination with Pembrolizumab in Subjects with Estrogen Receptor-positive ER Human Epidermal Growth Factor Receptor 2 HER2-negative Locally Advanced and Unresectable or Metastatic Breast Cancer Expressing Somatostatin Receptors SSTRs and Progressed After Antibody-drug Conjugates Andor Chemotherapy TRACY-1
Status:
RECRUITING
Status Verified Date:
2024-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
TRACY-1
Brief Summary:
Phase 1b2 open-label trial of 225Ac-DOTATATE RYZ101 alone and with pembrolizumab in subjects with ER HER2-negative unresectable or metastatic breast cancer expressing SSTRs
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None